Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib

Posted by rob on February 18, 2012 under Uncategorized | Comments are off for this article

Ling Li, Lisheng Wang, Liang Li, Zhiqiang Wang, Yinwei Ho, Tinisha McDonald, Tessa L. Holyoake, WenYong Chen, Ravi Bhatia. BCR-ABL tyrosine kinase inhibitors (TKI) fail to eliminate quiescent leukemia stem cells (LSC) in chronic myelogenous leukemia (CML). Thus, strategies targeting LSC are required to achieve cure. W…. (Source: Cancer Cell)
More